FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2457-2471 June 14, 2007 Number 24 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Psaty, B. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been determined.

Methods We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clinical-trials registry maintained by the drug manufacturer (GlaxoSmithKline). Criteria for inclusion in our meta-analysis included a study duration of more than 24 weeks, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes. Of 116 potentially relevant studies, 42 trials met the inclusion criteria. We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.

Results Data were combined by means of a fixed-effects model. In the 42 trials, the mean age of the subjects was approximately 56 years, and the mean baseline glycated hemoglobin level was approximately 8.2%. In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval [CI], 1.03 to 1.98; P=0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P=0.06).

Conclusions Rosiglitazone was associated with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance. Our study was limited by a lack of access to original source data, which would have enabled time-to-event analysis. Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.

Source Information

From the Cleveland Clinic, Cleveland.

This article (10.1056/NEJMoa072761) was published at www.nejm.org on May 21, 2007.

Address reprint requests to Dr. Nissen at the Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Ave., Cleveland, OH 44195, or at nissens{at}ccf.org.

Full Text of this Article

Related Letters:

Rosiglitazone and Cardiovascular Risk
Bracken M. B., Mannucci E., Monami M., Marchionni N., Diamond G. A., Kaul S., Brett A. S., Nissen S. E., Wolski K., Psaty B. M., Furberg C. D.
Extract | Full Text | PDF  
N Engl J Med 2007; 357:937-940, Aug 30, 2007. Correspondence

This article has been cited by other articles:

• Tao, L., Wang, Y., Gao, E., Zhang, H., Yuan, Y., Lau, W. B., Chan, L., Koch, W. J., Ma, X. L. (2010). Adiponectin: An Indispensable Molecule in Rosiglitazone Cardioprotection Following Myocardial Infarction. Circ. Res. 106: 409-417 [Abstract] [Full Text]  
• McNutt, R. A., Livingston, E. H. (2010). Evidence-Based Medicine Requires Appropriate Clinical Context. JAMA 303: 454-455 [Full Text]  
• Butler, P. C., Dry, S., Elashoff, R. (2010). GLP-1-Based Therapy for Diabetes: What You Do Not Know Can Hurt You. Diabetes Care 33: 453-455 [Full Text]  
• Halvorsen, B., Heggen, E., Ueland, T., Smith, C., Sandberg, W. J, Damas, J. K, Otterdal, K., Tonstad, S., Aukrust, P. (2010). Treatment with the PPAR{gamma} agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome. Eur J Endocrinol 162: 267-273 [Abstract] [Full Text]  
• Tomlinson, G., Detsky, A. S. (2010). Composite End Points in Randomized Trials: There Is No Free Lunch. JAMA 303: 267-268 [Full Text]  
• Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., Stanley, W. C. (2010). Myocardial Fatty Acid Metabolism in Health and Disease. Physiol. Rev. 90: 207-258 [Abstract] [Full Text]  
• Aronson, J. (2010). When I Use a word ... Changing your practice. QJM 103: 63-65 [Full Text]  
• Cheatham, W. W. (2010). Peroxisome proliferator-activated receptor translational research and clinical experience. Am. J. Clin. Nutr. 91: 262S-266S [Abstract] [Full Text]  
• Higuchi, A., Ohashi, K., Shibata, R., Sono-Romanelli, S., Walsh, K., Ouchi, N. (2010). Thiazolidinediones Reduce Pathological Neovascularization in Ischemic Retina Via an Adiponectin-Dependent Mechanism. Arterioscler. Thromb. Vasc. Bio. 30: 46-53 [Abstract] [Full Text]  
• Kahn, S. E., Haffner, S. M., Viberti, G., Herman, W. H., Lachin, J. M., Kravitz, B. G., Yu, D., Paul, G., Holman, R. R., Zinman, B., for A Diabetes Outcome Progression Trial (ADOPT) S, (2010). Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 33: 177-183 [Abstract] [Full Text]  
• Sugii, S., Olson, P., Sears, D. D., Saberi, M., Atkins, A. R., Barish, G. D., Hong, S.-H., Castro, G. L., Yin, Y.-Q., Nelson, M. C., Hsiao, G., Greaves, D. R., Downes, M., Yu, R. T., Olefsky, J. M., Evans, R. M. (2009). PPAR{gamma} activation in adipocytes is sufficient for systemic insulin sensitization. Proc. Natl. Acad. Sci. USA 106: 22504-22509 [Abstract] [Full Text]  
• Rao, Y. K., Lee, M.-J., Chen, K., Lee, Y.-C., Wu, W.-S., Tzeng, Y.-M. (2009). Insulin-mimetic Action of Rhoifolin and Cosmosiin Isolated from Citrus grandis (L.) Osbeck Leaves: Enhanced Adiponectin Secretion and Insulin Receptor Phosphorylation in 3T3-L1 Cells. Evid Based Complement Alternat Med 0: nep204v1-nep204 [Abstract] [Full Text]  
• Tzoulaki, I., Molokhia, M., Curcin, V., Little, M. P, Millett, C. J, Ng, A., Hughes, R. I, Khunti, K., Wilkins, M. R, Majeed, A., Elliott, P. (2009). Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339: b4731-b4731 [Abstract] [Full Text]  
• Hennekens, C. H., DeMets, D. (2009). The Need for Large-Scale Randomized Evidence Without Undue Emphasis on Small Trials, Meta-analyses, or Subgroup Analyses. JAMA 302: 2361-2362 [Full Text]  
• Lipscombe, L. L (2009). Rosiglitazone was non-inferior to metformin plus sulphonylurea for CV events but increased risk of HF and fractures in type 2 diabetes. Evid. Based Med. 14: 168-168 [Full Text]  
• Kroese, J. M., Mooij, C. F, van der Graaf, M., Hermus, A. R M M, Tack, C. J (2009). Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia. Eur J Endocrinol 161: 887-894 [Abstract] [Full Text]  
• Nicholas, A. S., Nadeau, D. A., Johnson, a. C. L. (2009). Treatment Considerations for Diabetes: A Pharmacist's Guide to Improving Care in the Elderly. Journal of Pharmacy Practice 22: 575-587 [Abstract]  
• KENNEDY, L. (2009). Incretin-based therapies for type 2 diabetes mellitus: New therapeutic mechanisms. Cleveland Clinic Journal of Medicine 76: S2-S3 [Full Text]  
• Hollander, P., Li, J., Allen, E., Chen, R., for the CV181-013 Investigators, (2009). Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone. J. Clin. Endocrinol. Metab. 94: 4810-4819 [Abstract] [Full Text]  
• Mirmirani, P., Karnik, P. (2009). Lichen Planopilaris Treated With a Peroxisome Proliferator-Activated Receptor {gamma} Agonist. Arch Dermatol 145: 1363-1366 [Full Text]  
• Lyon, C. M., Klinge, D. M., Do, K. C., Grimes, M. J., Thomas, C. L., Damiani, L. A., March, T. H., Stidley, C. A., Belinsky, S. A. (2009). Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model. Carcinogenesis 30: 2095-2099 [Abstract] [Full Text]  
• Nofziger, C., Blazer-Yost, B. L. (2009). PPAR{gamma} Agonists, Modulation of Ion Transporters, and Fluid Retention. J. Am. Soc. Nephrol. 20: 2481-2483 [Full Text]  
• Philbrick, A. M., Ernst, M. E., McDanel, D. L., Ross, M. B., Moores, K. G. (2009). Metformin use in renal dysfunction: Is a serum creatinine threshold appropriate?. Am J Health Syst Pharm 66: 2017-2022 [Abstract] [Full Text]  
• Vedula, S. S., Bero, L., Scherer, R. W., Dickersin, K. (2009). Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use. NEJM 361: 1963-1971 [Abstract] [Full Text]  
• Amoruso, A., Bardelli, C., Fresu, L. G., Palma, A., Vidali, M., Ferrero, V., Ribichini, F., Vassanelli, C., Brunelleschi, S. (2009). Enhanced Peroxisome Proliferator-Activated Receptor-{gamma} Expression in Monocyte/Macrophages from Coronary Artery Disease Patients and Possible Gender Differences. J. Pharmacol. Exp. Ther. 331: 531-538 [Abstract] [Full Text]  
• Bain, J. R., Stevens, R. D., Wenner, B. R., Ilkayeva, O., Muoio, D. M., Newgard, C. B. (2009). Metabolomics Applied to Diabetes Research: Moving From Information to Knowledge. Diabetes 58: 2429-2443 [Full Text]  
• Nilsson, P. M. (2009). Hypertension and Diabetes: Should We Treat Early Surrogates?: What are the cons?. Diabetes Care 32: S290-S293 [Full Text]  
• Kassem, S. A., Raz, I. (2009). Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No. Diabetes Care 32: S337-S341 [Full Text]  
• Bianchi, C., Miccoli, R., Daniele, G., Penno, G., Del Prato, S. (2009). Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes. Diabetes Care 32: S342-S348 [Full Text]  
• Kleinhenz, J. M., Kleinhenz, D. J., You, S., Ritzenthaler, J. D., Hansen, J. M., Archer, D. R., Sutliff, R. L., Hart, C. M. (2009). Disruption of endothelial peroxisome proliferator-activated receptor-{gamma} reduces vascular nitric oxide production. Am. J. Physiol. Heart Circ. Physiol. 297: H1647-H1654 [Abstract] [Full Text]  
• Koppen, A., Houtman, R., Pijnenburg, D., Jeninga, E. H., Ruijtenbeek, R., Kalkhoven, E. (2009). Nuclear Receptor-Coregulator Interaction Profiling Identifies TRIP3 as a Novel Peroxisome Proliferator-activated Receptor {gamma} Cofactor. Mol. Cell. Proteomics 8: 2212-2226 [Abstract] [Full Text]  
• Kavoussi, S.K., Witz, C.A., Binkley, P.A., Nair, A.S., Lebovic, D.I. (2009). Peroxisome-proliferator activator receptor-gamma activation decreases attachment of endometrial cells to peritoneal mesothelial cells in an in vitro model of the early endometriotic lesion. Mol Hum Reprod 15: 687-692 [Abstract] [Full Text]  
• Raj, S. R., Stein, C. M., Saavedra, P. J., Roden, D. M. (2009). Cardiovascular Effects of Noncardiovascular Drugs. Circulation 120: 1123-1132 [Full Text]  
• Kelly, T. N., Bazzano, L. A., Fonseca, V. A., Thethi, T. K., Reynolds, K., He, J. (2009). Systematic Review: Glucose Control and Cardiovascular Disease in Type 2 Diabetes. ANN INTERN MED 151: 394-403 [Abstract] [Full Text]  
• Hirsch, L. J. (2009). Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications: The Tort Bar and Editorial Oversight of Medical Journals. Mayo Clin Proc. 84: 811-821 [Full Text]  
• Yang, L., Xu, L., He, L. (2009). A CitationRank algorithm inheriting Google technology designed to highlight genes responsible for serious adverse drug reaction. Bioinformatics 25: 2244-2250 [Abstract] [Full Text]  
• Potenza, M. A., Gagliardi, S., De Benedictis, L., Zigrino, A., Tiravanti, E., Colantuono, G., Federici, A., Lorusso, L., Benagiano, V., Quon, M. J., Montagnani, M. (2009). Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature. Am. J. Physiol. Endocrinol. Metab. 297: E685-E694 [Abstract] [Full Text]  
• Yates, T, Davies, M, Khunti, K (2009). Preventing type 2 diabetes: can we make the evidence work?. Postgrad. Med. J. 85: 475-480 [Abstract] [Full Text]  
• Juurlink, D. N, Gomes, T., Lipscombe, L. L, Austin, P. C, Hux, J. E, Mamdani, M. M (2009). Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 339: b2942-b2942 [Abstract] [Full Text]  
• Xie, S., Lee, Y.-F., Kim, E., Chen, L.-M., Ni, J., Fang, L.-Y., Liu, S., Lin, S.-J., Abe, J.-i., Berk, B., Ho, F.-M., Chang, C. (2009). TR4 nuclear receptor functions as a fatty acid sensor to modulate CD36 expression and foam cell formation. Proc. Natl. Acad. Sci. USA 106: 13353-13358 [Abstract] [Full Text]  
• Rabkin, S. W., Lodha, P. (2009). Stearic acid-induced cardiac lipotoxicity is independent of cellular lipid and is mitigated by the fatty acids oleic and capric acid but not by the PPAR agonist troglitazone. Exp Physiol 94: 877-887 [Abstract] [Full Text]  
• Saraf, S., Nishtala, S., Parretti, H., Capps, N., Ramachandran, S. (2009). Paradoxical fall in HDL cholesterol observed in a patient treated with rosiglitazone and pioglitazone. British Journal of Diabetes & Vascular Disease 9: 186-189  
• Chaggar, P. S., Shaw, S. M., Williams, S. G. (2009). Review article: Thiazolidinediones and heart failure. Diabetes and Vascular Disease Research 6: 146-152 [Abstract]  
• Hemmingsen, B., Lund, S. S, Wetterslev, J., Vaag, A. (2009). Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol 161: 1-9 [Abstract] [Full Text]  
• Yang, L., Luo, H., Chen, J., Xing, Q., He, L. (2009). SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucleic Acids Res 37: W406-W412 [Abstract] [Full Text]  
• Brooks, A. M., Thacker, S. M (2009). Dapagliflozin for the Treatment of Type 2 Diabetes. The Annals of Pharmacotherapy 43: 1286-1293 [Abstract] [Full Text]  
• Jones, A., Deb, R., Torsney, E., Howe, F., Dunkley, M., Gnaneswaran, Y., Gaze, D., Nasr, H., Loftus, I. M., Thompson, M. M., Cockerill, G. W. (2009). Rosiglitazone Reduces the Development and Rupture of Experimental Aortic Aneurysms. Circulation 119: 3125-3132 [Abstract] [Full Text]  
• Allen, L. A., Hernandez, A. F., O'Connor, C. M., Felker, G. M. (2009). End points for clinical trials in acute heart failure syndromes.. J Am Coll Cardiol 53: 2248-2258 [Abstract] [Full Text]  
• The BARI 2D Study Group, (2009). A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. NEJM 360: 2503-2515 [Abstract] [Full Text]  
• Lonn, E. M., Gerstein, H. C., Sheridan, P., Smith, S., Diaz, R., Mohan, V., Bosch, J., Yusuf, S., Dagenais, G. R., DREAM (Diabetes REduction Assessment with ramipril, (2009). Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).. J Am Coll Cardiol 53: 2028-2035 [Abstract] [Full Text]  
• St. Onge, E. L., Miller, S. A., Taylor, J. R. (2009). Novel Approaches to the Treatment of Type 2 Diabetes. Journal of Pharmacy Practice 22: 320-332 [Abstract]  
• Takagi, T., Okura, H., Kobayashi, Y., Kataoka, T., Taguchi, H., Toda, I., Tamita, K., Yamamuro, A., Sakanoue, Y., Ito, A., Yanagi, S., Shimeno, K., Waseda, K., Yamasaki, M., Fitzgerald, P. J., Ikeno, F., Honda, Y., Yoshiyama, M., Yoshikawa, J., for the POPPS Investigators, (2009). A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). J Am Coll Cardiol Intv 2: 524-531 [Abstract] [Full Text]  
• Nissen, S. E. (2009). Pioglitazone to Reduce Restenosis After Bare-Metal Stent Placement?. J Am Coll Cardiol Intv 2: 532-533 [Full Text]  
• Hall, G. M., Nicholson, G. (2009). Current Therapeutic Drugs for Type 2 Diabetes, Still Useful After 50 Years?. Anesth. Analg. 108: 1727-1730 [Full Text]  
• Nakaya, H., Summers, B. D., Nicholson, A. C., Gotto, A. M. Jr., Hajjar, D. P., Han, J. (2009). Atherosclerosis in LDLR-Knockout Mice Is Inhibited, but Not Reversed, by the PPAR{gamma} Ligand Pioglitazone. Am. J. Pathol. 174: 2007-2014 [Abstract] [Full Text]  
• Banarer, S., Luan, F. L., Duckworth, W. C., Moritz, T., Abraira, C. (2009). Glucose Control and Vascular Complications in Type 2 Diabetes. NEJM 360: 2031-2032 [Full Text]  
• Szeto, C.-C., Chow, K.-M. (2009). THIAZOLIDINEDIONES IN PERITONEAL DIALYSIS PATIENTS. pdi 29: 248-251 [Full Text]  
• Gellad, W. F., Detsky, A. S., Choudhry, N. K. (2009). Implications of recent clinical trials on pay-for-performance. Am J Health Syst Pharm 66: 864-867 [Full Text]  
• Nathan, D. M., for the American Diabetes Association and European, (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes: Response to Cobitz and Ambery. Diabetes Care 32: e59-e59 [Full Text]  
• Ramirez, S. P.B., Albert, J. M., Blayney, M. J., Tentori, F., Goodkin, D. A., Wolfe, R. A., Young, E. W., Bailie, G. R., Pisoni, R. L., Port, F. K. (2009). Rosiglitazone Is Associated with Mortality in Chronic Hemodialysis Patients. J. Am. Soc. Nephrol. 20: 1094-1101 [Abstract] [Full Text]  
• Flaherty, M. L., Adeoye, O., Sekar, P., Haverbusch, M., Moomaw, C. J., Tao, H., Broderick, J. P., Woo, D. (2009). The Challenge of Designing a Treatment Trial for Warfarin-Associated Intracerebral Hemorrhage. Stroke 40: 1738-1742 [Abstract] [Full Text]  
• Brice, R. (2009). A taxi driver with type 2 diabetes. BMJ 338: b1369-b1369 [Full Text]  
• Morrow, D. A., Scirica, B. M., Chaitman, B. R., McGuire, D. K., Murphy, S. A., Karwatowska-Prokopczuk, E., McCabe, C. H., Braunwald, E., for the MERLIN-TIMI 36 Investigators, (2009). Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled Trial. Circulation 119: 2032-2039 [Abstract] [Full Text]  
• Evans-Molina, C., Robbins, R. D., Kono, T., Tersey, S. A., Vestermark, G. L., Nunemaker, C. S., Garmey, J. C., Deering, T. G., Keller, S. R., Maier, B., Mirmira, R. G. (2009). Peroxisome Proliferator-Activated Receptor {gamma} Activation Restores Islet Function in Diabetic Mice through Reduction of Endoplasmic Reticulum Stress and Maintenance of Euchromatin Structure. Mol. Cell. Biol. 29: 2053-2067 [Abstract] [Full Text]  
• Vanasse, A., Carpentier, A. C., Courteau, J., Asghari, S. (2009). Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients. Diabetes and Vascular Disease Research 6: 87-93 [Abstract]  
• Olin, J. L., Spooner, L. M. (2009). Introduction: Cardiovascular Therapeutics. Journal of Pharmacy Practice 22: 133-134  
• Cheng, J. W. M., Bhatt, S. H., Goldman-Levine, J. D. (2009). The Benefit and Risk of Antidiabetic Agents Used in Patients With Heart Disease. Journal of Pharmacy Practice 22: 179-193 [Abstract]  
• Flory, J. H., Ellenberg, S., Szapary, P. O., Strom, B. L., Hennessy, S. (2009). Antidiabetic Action of Bezafibrate in a Large Observational Database. Diabetes Care 32: 547-551 [Abstract] [Full Text]  
• Meredith, D., Panchatcharam, M., Miriyala, S., Tsai, Y.-S., Morris, A. J., Maeda, N., Stouffer, G. A., Smyth, S. S. (2009). Dominant-Negative Loss of PPAR{gamma} Function Enhances Smooth Muscle Cell Proliferation, Migration, and Vascular Remodeling. Arterioscler. Thromb. Vasc. Bio. 29: 465-471 [Abstract] [Full Text]  
• Mathieu, P., Poirier, P., Pibarot, P., Lemieux, I., Despres, J.-P. (2009). Visceral Obesity: The Link Among Inflammation, Hypertension, and Cardiovascular Disease. Hypertension 53: 577-584 [Full Text]  
• Campbell, I. W (2009). Review: Durable glycaemia -- the promised land. British Journal of Diabetes & Vascular Disease 9: 53-63 [Abstract]  
• Song, S. H, Gray, T. A (2009). Management of type 2 diabetes and lipids: a critique of the NICE guidelines 2008. British Journal of Diabetes & Vascular Disease 9: 69-74 [Abstract]  
• Koh, K. K., Oh, P. C., Quon, M. J. (2009). Does reversal of oxidative stress and inflammation provide vascular protection?. Cardiovasc Res 81: 649-659 [Abstract] [Full Text]  
• Wood, A. J.J. (2009). Progress and Deficiencies in the Registration of Clinical Trials. NEJM 360: 824-830 [Full Text]  
• Horton, E. S. (2009). Defining the role of basal and prandial insulin for optimal glycemic control.. J Am Coll Cardiol 53: S21-S27 [Abstract] [Full Text]  
• HOOGWERF, B. J. (2009). IN REPLY:. Cleveland Clinic Journal of Medicine 76: 83-84 [Full Text]  
• Haneda, M., Morikawa, A. (2009). Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?. Nephrol Dial Transplant 24: 338-341 [Full Text]  
• Havas, S. (2009). The ACCORD Trial and Control of Blood Glucose Level in Type 2 Diabetes Mellitus: Time to Challenge Conventional Wisdom. Arch Intern Med 169: 150-154 [Full Text]  
• Loke, Y. K. MBBS MD, Singh, S. MD MPH, Furberg, C. D. MD PhD (2009). Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180: 32-39 [Abstract] [Full Text]  
• Lipscombe, L. L. MD MSc (2009). Thiazolidinediones: Do harms outweigh benefits?. CMAJ 180: 16-17 [Full Text]  
• Lindsey, J. B, Cipollone, F., Abdullah, S. M, Mcguire, D. K (2009). Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diabetes and Vascular Disease Research 6: 7-14 [Abstract]  
• van Hooland, S., Boey, O., Van der Niepen, P., Van den Branden, C., Verbeelen, D. (2009). Effect of Short-Term Rosiglitazone Therapy in Peritoneal Dialysis Patients. pdi 29: 108-111 [Full Text]  
• Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Clin. Diabetes 27: 4-16 [Full Text]  
• Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Spectr. 22: 6-17 [Full Text]  
• Ondrey, F. (2009). Peroxisome Proliferator-Activated Receptor {gamma} Pathway Targeting in Carcinogenesis: Implications for Chemoprevention. Clin. Cancer Res. 15: 2-8 [Abstract] [Full Text]  
• Joy, M. S., Gipson, D. S., Dike, M., Powell, L., Thompson, A., Vento, S., Eddy, A., Fogo, A. B., Kopp, J. B., Cattran, D., Trachtman, H. (2009). Phase I Trial of Rosiglitazone in FSGS: I. Report of the FONT Study Group. CJASN 4: 39-47 [Abstract] [Full Text]  
• Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B. (2009). Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193-203 [Abstract] [Full Text]  
• Jenkins, D. J. A., Kendall, C. W. C., McKeown-Eyssen, G., Josse, R. G., Silverberg, J., Booth, G. L., Vidgen, E., Josse, A. R., Nguyen, T. H., Corrigan, S., Banach, M. S., Ares, S., Mitchell, S., Emam, A., Augustin, L. S. A., Parker, T. L., Leiter, L. A. (2008). Effect of a Low-Glycemic Index or a High-Cereal Fiber Diet on Type 2 Diabetes: A Randomized Trial. JAMA 300: 2742-2753 [Abstract] [Full Text]  
• Michaelson, J. (2008). Thiazolidinedione associated volume overload and pulmonary hypertension. Ther Adv Cardiovasc Dis 2: 435-438 [Abstract]  
• Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., Eckel, R. H. (2008). The Metabolic Syndrome. Endocr. Rev. 29: 777-822 [Abstract] [Full Text]  
• Beysen, C., Murphy, E. J., Nagaraja, H., Decaris, M., Riiff, T., Fong, A., Hellerstein, M. K., Boyle, P. J. (2008). A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. J. Lipid Res. 49: 2657-2663 [Abstract] [Full Text]  
• Winkelmayer, W. C., Setoguchi, S., Levin, R., Solomon, D. H. (2008). Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy. Arch Intern Med 168: 2368-2375 [Abstract] [Full Text]  
• Von Bibra, H., Diamant, M., Scheffer, P. G, Siegmund, T., Schumm-Draeger, P.-M. (2008). Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. Diabetes and Vascular Disease Research 5: 310-318 [Abstract]  
• Shah, A., Mehta, N., Reilly, M. P. (2008). Adipose Inflammation, Insulin Resistance, and Cardiovascular Disease. JPEN J Parenter Enteral Nutr 32: 638-644 [Abstract] [Full Text]  
• Chitturi, S. (2008). Review: Treatment options for nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology 1: 173-189 [Abstract]